NCT02294682 - A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

July 1, 2016

Study Completion Date

July 27, 2016

Conditions

Gonorrhea

Interventions

DRUG

GSK2140944

Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).

Trial Locations (14)

19046

GSK Investigational Site, Jenkintown

30308

GSK Investigational Site, Atlanta

32806

GSK Investigational Site, Orlando

44109

GSK Investigational Site, Cleveland

46202

GSK Investigational Site, Indianapolis

68114

GSK Investigational Site, Omaha

70119

GSK Investigational Site, New Orleans

90028

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

92262

GSK Investigational Site, Palm Springs

92708

GSK Investigational Site, Fountain Valley

94103

GSK Investigational Site, San Francisco

00927

GSK Investigational Site, San Juan

SW10 9NH

GSK Investigational Site, London